Research progress on regulation of Ang/Tie signaling pathway in the treatment of ocular neovascular diseases
10.3760/cma.j.cn115989-20220618-00283
- VernacularTitle:调控Ang/Tie信号通路治疗眼底新生血管性疾病的研究进展
- Author:
Jingyan YANG
1
;
Wenbin WEI
Author Information
1. 首都医科大学附属北京同仁医院 北京同仁眼科中心 眼内肿瘤诊治研究北京市重点实验室 北京市眼科学与视觉科学重点实验室 医学人工智能研究与验证工信部重点实验室，北京 100730
- Keywords:
Retinal neovascularization;
Anti-neovascularization;
Ang/Tie pathway
- From:
Chinese Journal of Experimental Ophthalmology
2024;42(5):467-472
- CountryChina
- Language:Chinese
-
Abstract:
The emergence of anti-vascular endothelial growth factor (VEGF) therapy has reduced the overall incidence of blindness from ocular neovascular disease.However, frequent intravitreal injections of anti-VEGF therapy are required, which places a significant burden to patients and affects long-term benefits.The angiopoietin (Ang)/tyrosine kinase with immunoglobulin-like and endothelial growth factor-like domains (Tie) pathways are identified as potentially therapeutic regulators for ocular neovascular disease, with additional benefits over anti-VEGF-A therapy.For ocular neovascular diseases, three molecules targeting the Ang/Tie pathway have been studied in clinical trials and the data released, in which faricimab, a bispecific immunoglobulin G1 antibody targeting VEGF-A and Ang-2, entered phase Ⅲ studies and met primary clinical endpoints, and two dosing regimens with prolonged treatment intervals (12 and 16 weeks) of faricimab showed reliable efficacy.Overall, the regulation of Ang/Tie pathway provides a new treatment option for ocular neovascular diseases, and it is necessary to deeply understand the mechanism of action of the pathway and accumulate more clinical data in the future.
